Inceptionr LLC Increases Holdings in Amgen Inc. $AMGN

Inceptionr LLC lifted its holdings in Amgen Inc. (NASDAQ:AMGN) by 75.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,432 shares of the medical research company’s stock after acquiring an additional 2,337 shares during the period. Amgen accounts for approximately 0.5% of Inceptionr LLC’s holdings, making the stock its 24th biggest holding. Inceptionr LLC’s holdings in Amgen were worth $1,911,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Robeco Institutional Asset Management B.V. boosted its stake in Amgen by 10.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after purchasing an additional 43,884 shares during the period. Curtis Advisory Group LLC acquired a new stake in shares of Amgen during the fourth quarter worth $1,669,000. Adell Harriman & Carpenter Inc. boosted its position in shares of Amgen by 7.9% in the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock valued at $7,204,000 after acquiring an additional 1,609 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in shares of Amgen in the fourth quarter valued at about $22,441,000. Finally, Robinhood Asset Management LLC acquired a new position in shares of Amgen in the fourth quarter valued at about $17,526,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Morgan Stanley dropped their price objective on shares of Amgen from $340.00 to $333.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 8th. The Goldman Sachs Group set a $389.00 target price on shares of Amgen in a report on Friday, June 5th. Daiwa Securities Group cut their price target on Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research note on Wednesday, May 13th. UBS Group increased their price target on Amgen from $400.00 to $420.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Finally, Royal Bank Of Canada restated a “positive” rating on shares of Amgen in a research note on Thursday, June 18th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $356.62.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.85% of the stock is currently owned by corporate insiders.

Amgen Stock Up 1.5%

Shares of AMGN opened at $371.50 on Friday. Amgen Inc. has a one year low of $269.77 and a one year high of $391.29. The company has a market cap of $200.50 billion, a P/E ratio of 25.85, a P/E/G ratio of 3.70 and a beta of 0.41. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The firm has a 50 day simple moving average of $350.28 and a two-hundred day simple moving average of $351.63.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter last year, the business posted $4.90 EPS. The company’s revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Research analysts forecast that Amgen Inc. will post 22.31 EPS for the current fiscal year.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.